Acquisition

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

By

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.

Five things for Pharma Marketers to know: Wednesday, August 27

Five things for Pharma Marketers to know: Wednesday, August 27

By

Allergan sets a shareholder voting date, Novo describes the types of acquisitions it will consider, and the AstraZeneca-Pfizer talks can now reopen.

Roche spends $8.3B for lung drug

Roche spends $8.3B for lung drug

By

Roche has beat out rumored competitors GlaxoSmithKline and Sanofi in a run-off to acquire California biotech InterMune.

Five things for pharma marketers to know: Monday, August 25

Five things for pharma marketers to know: Monday, August 25

By

Roche backs away from Chugai but embraces InterMune, Merck rumored on track to score first PD-1 approval, a new Ebola strain may have surfaced and JNJ scoops up experimental anti-TNF.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.

InterMune joins M&A fray

GlaxoSmithKline, Actelion, Sanofi and Roche are said to be among a host of suitors.

Roche buys Santaris

Roche buys Santaris

By

The $250 million cash deal includes an additional $200 million in milestone payments.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.

AstraZeneca beefs up respiratory portfolio

AstraZeneca beefs up respiratory portfolio

By

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.

Docs not fans of Valeant-Allergan mix

The Wall Street Journal reports that 44% of dermatologists and plastic surgeons polled in a Sanford Bernstein survey said they would consider Botox alternatives if Allergan becomes a Valeant subsidiary.

Roche is hungry, not starving for M&A

CEO Severin Schwan tells Reuters that the Swiss firm will be looking for small acquisitions and partnerships.

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% of workforce

By

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.

Shire, AbbVie join forces for $55B

Shire, AbbVie join forces for $55B

By

The deal includes a $1.6-billion fee if AbbVie tries to walk away.

Salix heads to Ireland

Salix heads to Ireland

By

Salix Pharmaceuticals joins the tax-inversion migration by purchasing Cosmo Technologies.

Allergan updates pipeline

Allergan updates pipeline

By

Allergan's latest pipeline news was a mix of the good and the bad. The good: a potential Lucentis competitor is progressing. The bad: migraine medication Semprana has stalled.

IMS to buy Cegedim CRM

IMS to buy Cegedim CRM

By

IMS is offering $520 million cash to add Cegedim's CRM and strategic data business. Cegedim says it will use the money to pay down debt.

Shire rebuffs AbbVie

Dublin-based Shire is urging shareholders to back independence and ignore AbbVie's $46.4 billion bid.

Medtronic buys Covidien

The deal makes Medtronic the most recent company to seek out lower tax rates.

Allergan turns down Valeant

CEO David Pyott told Modern Healthcare that acquisition fallout would have probably included a pinched R&D budget and higher product prices.

Roche builds strength in molecular diagnostics

The company is buying Genia Technologies for $125 million.

Valeant ups the ante

In addition to raising its bid for Allergan, Valeant is lobbying for a shareholder meeting to oust six board members.

Valeant ups Allergan bid

The new offer is $49.4 billion.

Pfizer, AstraZeneca part ways

Pfizer, AstraZeneca part ways

By

Pfizer announced Monday that it will no longer pursue AstraZeneca, but industry watchers note it may not really be over.

Pfizer and AstraZeneca: what's next

Pfizer and AstraZeneca present their cases for and against a possible merger to UK lawmakers this week.

Sanofi snubs Allergan, Allergan snubs Valeant

Reports indicate Allergan's reported attempt to lure Sanofi and J&J into an partnership have failed, and that the Botox manufacturer has told Valeant to keep its takeover offer to itself.

AZ appeal for independence seen as bargaining chip

AZ appeal for independence seen as bargaining chip

By

The firm laid out reasons for why it should remain independent of Pfizer, but analysts say projected earnings are a bit too optimistic and could be a ploy to up the offer.

Bayer buys Merck OTC portfolio

Bayer buys Merck OTC portfolio

By

The $14.2-billion deal is expected to close in the second half of this year.

Pfizer posts weak Q1 sales, stands by AZ offer

Pfizer posts weak Q1 sales, stands by AZ offer

By

CEO Ian Read told investors Monday that an AZ merger would benefit Astra shareholders and add oomph to its marketing potential. Another exec said he could "envision" filing palbociclib this year, but made no promises.

Court idles Sun-Ranbaxy deal

Insider-trading allegations have temporarily stopped the merger.

Email Newsletters